Atossa Therapeutics Inc’s recent filing unveils that its Director Finn Jonathan acquired Company’s shares for reported $44250.0 on Apr 10 ’24. In the deal valued at $1.77 per share,25,000 shares were bought. As a result of this transaction, Finn Jonathan now holds 25,000 shares worth roughly $19250.0.
Maxim Group initiated its Atossa Therapeutics Inc [ATOS] rating to a Buy in a research note published on January 26, 2018; the price target was $2.
Price Performance Review of ATOS
On Friday, Atossa Therapeutics Inc [NASDAQ:ATOS] saw its stock fall -4.92% to $0.77. Over the last five days, the stock has lost -9.09%. Atossa Therapeutics Inc shares have fallen nearly -18.93% since the year began. Nevertheless, the stocks have fallen -14.48% over the past one year. While a 52-week high of $2.31 was reached on 01/03/25, a 52-week low of $0.72 was recorded on 01/30/25. SMA at 50 days reached $1.0089, while 200 days put it at $1.2855.
Levels Of Support And Resistance For ATOS Stock
The 24-hour chart illustrates a support level at 0.7444, which if violated will result in even more drops to 0.7233. On the upside, there is a resistance level at 0.8032. A further resistance level may holdings at 0.8409. The Relative Strength Index (RSI) on the 14-day chart is 29.63, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.0589, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 82.44%. Stochastics %K at 33.63% indicates the stock is a holding.
How much short interest is there in Atossa Therapeutics Inc?
A steep rise in short interest was recorded in Atossa Therapeutics Inc stocks on 2025-01-15, growing by 0.54 million shares to a total of 8.74 million shares. Yahoo Finance data shows the prior-month short interest on 2024-12-13 was 8.2 million shares. There was a rise of 6.15%, which implies that there is a positive sentiment for the stock.
